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Abstract 
Tuberculosis is an infectious disease, and different treatments have been discovered over the years. 
However, patients may develop various drug resistance levels that affect the likelihood of becoming cured or 
dying. In this study, we sought to employ data visualization to explore the relationship between treatment 
trajectory, as indicated by smear and culture results in the follow-up tests and patient outcomes. A large sample 
of patients have been broken down by demographics including age, gender, and drug resistance status. Sankey 
diagrams were used to visualize the pathway progression of the patients over time split between two time 
periods- months 0-6 and months 6-24. It was determined that the most crucial months of treatment for all drug 
resistant types were during months 0-2, since there was high variability within that time frame for all 
demographics. It was also observed that younger patients were much more varying test results. It is thus 
recommended that the standards be updated to test every month for the first nine months of treatment in order to 
better track the pathway variety and that younger patients be more closely monitored throughout the treatment 
process. Future studies may investigate the possibility of creating a prediction diagram for patient pathway 
progression based on demographic status and past medical information. 
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1. Background and Significance 
Tuberculosis (TB) is an infection caused by the bacteria called Mycobacterium tuberculosis, which may lay 
dormant in the body or be an active infection. It is most commonly located in the lungs, but the bacteria may 
also reside within other organs such as the kidney or spine. The bacteria is transmitted through the air 
whenever an infected individual coughs, sneezes, etc., and only a few of the germs are needed to be inhaled 
in order for another person to become infected. It should be noted, however, that approximately 25% of the 
world’s population has latent TB, who are not considered sick or able to transmit the disease. 
According to the World Health Organization (WHO), diagnosis and treatment of tuberculosis averts 
millions of death, but there is still improvement to be made in regards to patient treatment (WHO 2017). 
Since there are varying reasons why some people do not receive treatment, such as lack of healthcare or 
knowledge of infection, more efficient and effective diagnosis and treatment is necessary. In addition to an 
effective diagnosis and follow-up testing, patients are in need of proper treatment plans. Since people have 
varying levels of multidrug resistance (MDR) levels, different drug treatments may not be as effective for 
certain patients. In previous studies, the status of “multi-drug resistant” (MDR) tends to be the most 
threatening to patients, as those with MDR tend to suffer from higher death rates (Abdelbary 2017). There 
also exists a resistant level called “PanS,” which has different resistances than MDR, but is still a significant 
threat since there is no treatment regimen. It is thus best to detect drug resistance as soon as possible so that 
another drug treatment may be implemented for the patient, as diagrams of untreated TB generally assume a 
total duration of only 2 years until self-cure or death (Tiemersma et. al. 2011).  
Smear and culture tests are common follow-up tests for TB patients under treatment in order to 
monitor the progress of recovery. Smear tests study the signs for TB bacteria while culture tests indicate the 
growth of bacteria. Patient status falls into one of four possible categories, depending on whether the smear 
reading is positive or negative and whether the culture reading is positive or negative. According to Lab 
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Tests Online, when both smear and culture read positive, there is significant evidence to determine the 
presence of the TB micro-bacteria, and the patient is diagnosed as having tuberculosis. If only the smear is 
positive, the results are questionable, as the bacteria present may not be that of tuberculosis. If only the 
culture is positive, this is a rare occurrence, and usually indicates an error and that further testing is required. 
Whenever both smear and culture test as negative, it indicates that no tuberculosis bacteria is present 
(Chakravorty et. al. 2005). Using this information, patient prognosis can be tracked over time based on 
which of the four statuses possible.   
Although those previously conducted projects are beneficial to understanding how to prevent 
infection and contamination, this research will help already infected patients by knowing if they are being 
properly treated. If not, it can be determined earlier so that more patients may start getting healthier sooner.  
1.1 Past-Related Tuberculosis Studies 
Currently, most tuberculosis studies have been concerned with factors that impact the infection of 
tuberculosis and how to better prevent the infection from developing (Wallis et. al. 2013). For example, the 
Tanzania study determined that smoking and HIV positivity are significant risk factors for mortality 
(Senkoro et. al. 2010, Mollel and Chilongola 2017, Philips et. al. 2017). These preexisting health concerns 
usually indicate that the patients begin treatment at some drug resistant level, making treatment even more 
difficult.  
It has also been determined that diabetes and multi-drug resistance are risk factors 
for cavitary disease, usually a result of prolonged untreated TB (Zhang et. al. 2016 and Raznatovska and 
Khudiakov 2018). This indicates that although untreated TB may not directly result in death, it often leads 
to further health problems (Chan, Edward D. 2004). Since so many patients may begin treatment with some 
form of drug resistance level, the development of TB drug treatments is vital in progression of disease 
treatment (Wallis et. al. 2016).  
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The idea of determining optimal treatment combinations is a fairly recent development within the 
medical and engineering community. There have already been projects dedicated to determining a drug 
combination that results in the highest yield of cured patients with the lowest death yield (Vite 2014 and 
Ahuja Shama D. 2011). Recently, many studies are being conducted to visualize complex medical process 
for simpler understanding (Lerner 1996, Loorak et. al. 2016, Laptev, Orlov, and Dragunova 2017, and 
Alemasoom et. al. 2014). 
1.2 Sankey Diagrams 
The first draft of a flow diagram based on volume, perhaps the most commonly known diagram resembling 
the Sankey diagram principles, was completed in 1869 by Charles Joseph Minard illustrating the size of 
Napoleon’s army during the Russian campaign of 1812-1813 (Minard). This graph shows the population of 
Napoleon’s army was much larger at the beginning of the campaign, then slowly diminished over time and 
distance until Napoleon returned from Russia with considerably depleted forces.  
The “Sankey diagram” itself was coined by Captain Matthew Henry Phineas Riall Sankey in 1898 in 
order to demonstrate the efficiency of a steam engine by visualizing the volume of energy (in this case, 
steam) moving throughout the system and its destinations. This visual allowed easier comprehension of 
wasted energy and demonstrating where heat was leaving and entering the engine. Sankey himself intended 
the diagram to mainly be used for energy flows within a confined system (Unknown, 1926).  
Commercially, the concept of visualizing the data in an engaging way makes communicating ideas 
much more attractive for both engineers and clients. Since the eyes naturally are drawn to arrows with a 
larger width, this makes drawing attention to the most significant flows much easier, and if the arrow 
diminishes over time, then that makes the change between the two appear even more drastic.  
This mapping of patient volume over time will be beneficial since it will clearly demonstrate the 
volume of patients that are being cured and the number of patients who die due to incomplete or insufficient 
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treatment. Khan et. al. (2015) used the Sankey diagram to better understand the trends of breast cancer 
patients, demonstrating its usage in the medical field.  
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2. Materials and Methodology 
The data was collected for Informational Monitoring and Evaluation System of National Control Program of 
Tuberculosis in the Republic of Moldova (SYME TB) over the course of 2009 to 2016. Patients were only 
included in the data set if testing proved susceptibility to infection, preventing any unconfirmed tuberculosis 
patients from being included. The set of data is composed of the clinical records of 23,160 tuberculosis patients 
from diagnosis to the end of treatment. The dataset was cleaned and prepared by Maryam Alimohammadi. 
For each patient, attributes were collected, and these attributes have been further divided into either a 
variable or a covariate. The covariate is the independent variable impacting the outcome of the dependent 
variables. The relevant divisions are as follows:  
a. Covariates: Gender (Male or Female), Age (less than 35 years of age, between ages 35 and 55, and 
greater than 55 years of age), TB group (MDR, PanS, or Neither)  
b. Variables: Smear, Culture, and Culture-Grade 
By the end of the 2-year time study, there is an additional response variable designated “Final_Status,” 
indicating if the patient’s status classified as “Cured,” “Not Cured,” or “Death.” Based on the NIH 
definition (WHO 2010), to obtain the “Cured” status for non-MDR classified patients, there must be at least two 
consecutive smear/culture teats with negative readings. However, for MDR patients, there must be at least three 
consecutive time periods of negative smear/culture test readings. The “Death” status is designated to any patient 
who dies for any reason within the 24 month period. Cases that are neither “Cured” or “Death” cases are 
designated as “Not Cured.” The percentages of each demographic was determined (Figure 1). 
Variable  Levels  Level Population  Description (if necessary)  
Gender  Male  76.715%    
  Female  23.285%    
Age Group  1   39.468%  Less than 35 years of age  
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  2   44.038%  Between 35 and 55 years of age  
  3  16.494%  Greater than 55 years of age  
TB Group  MDR  23.246%  Multi-drug Resistance  
  PanS  65.782%  Susceptible to both Isoniazid and 
Rifampicin  
  Neither  10.972%    
Final Status  Cured  82.347%    
  Death  5.753%    
  Not Cured  11.9%    
Figure 1: Dataset Attribute Analysis 
2.1 Research Objectives 
The main objective of this research project was using data visualization in order to demonstrate patient 
treatment progression within certain demographics. By analyzing the typical trends of the treatment pathways of 
different demographics, the decision-making process for future TB treatment could be improved. Analyzing 
trends may also allow a better understanding of what groups are more at risk when diagnosed with a TB 
infection.   
2.2 Methodology 
The first main task of this project was developing programing code that would count the number of patients 
traveling along each possible path according to appropriate measures. Once all the possible paths were properly 
accounted for, a new Excel data file was created, only listing the pathways with non-zero values. This data set 
was then be loaded into Power BI for visualization. The visualization was completed using the Sankey Diagram 
extension on Microsoft’s Power BI, available for free download online. The visual was then rearranged in order 
to correspond with the defined layout of the axis.  
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2.3 Key Assumptions 
Before programming could begin, key assumptions had to be established, as the big data was not perfect and 
had to be cleansed for proper diagraming. The key assumptions are as follows:  
a. If a patient missed a check-up session, then it is assumed that his or her status remained unchanged 
until the next check-up attended  
b. This project would only be concerned with the patients who had test readings at time 0. This is to 
ensure that only patients present for the full two years are analyzed.  
c. Smear would only be classified as “Positive” or “Negative”. Although the dataset had varying 
degrees of smear positivity, in order to maintain simplicity in the diagram, culture was the only 
reading accounting for varying degrees. 
d. Since Smear indicates the presence of the TB bacteria, any culture readings would be considered 
false positives, since culture reads the severity of the infection. Therefore, Negative Smear only has 
a 0 Culture grade, but Positive Smear has varying grades of Culture. 
e. If a patient were to leave the system before the time study deadline of 24 months with the status 
“Not Cured,” they would be counted as in the “Death” category. This is due to the fact that if the 
patient weren’t cured yet, it is assumed that they would continue treatment before the 24 month time 
period was up. The only time “Death” and “Not Cured” are differentiated is in the final month.  
2.4 Program Diagraming 
The programming was completed using formulas already installed in Excel. In order for this visualization to 
form properly, the data was arranged in a format mapping out the quantities from origins to targets. This 
determined that in addition to the programming separating the data according to different demographics, it had 
to be recorded in a specific way in order to create a Sankey diagram in accordance with the extension 
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requirements. The following format required for the Sankey diagram is similar to the example below (Figure 
2).   
Origin  Target  Quantity  
A  B  10  
A  C  2  
B  D  7 
Figure 2: Sankey Diagram Sample 
2.5 Sankey Diagram Design 
For each diagram, the y-axis is a reading of the patient’s status, with the positive direction indicating 
improvement and the negative direction signifying health decline. Since each test reading contains a smear and 
culture reading, the axis is sorted first by smear reading, with negative readings lying on the positive direction 
of the y-axis, then by culture, with lower positive readings lying in the positive y-axis direction. The x-
axis demonstrates the progression over time in units of months.   
In order to keep the diagrams relatively simple, the diagrams are broken up into 2 distinct time periods: 
Month 1-6 and Month 6-24. Since the first 6 months are the most crucial in the treatment process, it was 
deemed important that those months be separated from the later months of testing. Each age group can be seen 
off to the side (A for age group 1, B for age group 2, C for age group 3), and the number of patients included in 
the first time period of the figure. 
In addition to separating the charts into different time periods, they are also divided according to various 
patient demographics. First, the pathways were constructed when only separated by two categories- gender and 
drug status. Drug status is the most crucial demographic to study, as this is the most impactful attribute directing 
patient treatment progression. In addition to drug resistance level, the patients were also separated based on 
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gender, since this was more insightful than separation based on age groups. Once the Gender/TB Group graphs 
were completed, they were further broken down based on age groups within each demographic.  
It was deemed vital that the diagrams were overall organized with a clear direction for decline and 
improvement. Since the diagrams are automatically generated by the program, any visual complication is not 
intentional. 
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3. Diagram Results 
In this section, each general diagram will be analyzed before being broken down according to age groups. This 
general analysis of a broader group further broken down with the more specific graphs allowed further insight 
into an initial broad analysis. Within each section, the different month sets can be seen, each further broken 
down by age group.  
3.1 Male MDR 
For the first 6 months within this demographic, most patients don’t change test results between intervals 
(Figure 3). In month 1, the only patients who died were previously tested with readings of negative smear 
results. However, later in month 5, the only patients designated with “Death” had previously had positive smear 
and culture readings, but this is to be expected. Throughout the 6 month period, there are multiple cases of 
patients with positive TB readings being designated as “Cured” in the next time period. The majority of cured 
patients previously tested having no signs of smear, but from the patients who had previously shown signs of 
smear, there was an even distribution getting cured. 
During the remaining months, the patients were much more stagnant in test readings, with relatively few 
patients classified as “Cured” or “Dead” in each time period. In the last time period, however, there were no 
deaths occurring, only instances of patients becoming designated as “Cured” or continuing treatment (Figure 
4). 
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3.1.1. Month 0-6 
 
Figure 3: Sankey Diagram for Male MDR Patients Months 0-6 
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3.1.2. Month 6-24 
 
 
Figure 4: Sankey Diagram for Male MDR Patients Months 6-24 
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3.2 Female MDR 
During the first 6 months, the only occurring deaths were in age groups 1 and 2 (Figures 5a and 5b), so this 
may signify that younger patients are more at risk for death during this first time period. However, the most 
patients recorded as being cured were also in the first two age groups, so this could also signify that the younger 
ages work in more extremes. That is to say, younger patients don’t tend to stay stagnant in treatment status and 
are quicker to reaching either a “Cured” or “Death” status within the first six months of treatment. 
For the remaining 18 months, there were few instances of degrading in test results before dying. Instead, 
most patients stayed within the past test reading, only moving when exiting the system. Again, there were no 
deaths recorded in the final time period, but there appeared to be significant portions of patients dying in other 
months, with the most deaths occurring in either age group 1 or 2 (Figures 6a and 6b). 
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3.2.1. Month 0-6 
 
Figure 5: Sankey Diagram of Female MDR Patients Months 0-6 
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3.2.2. Month 6-24 
 
Figure 6: Sankey Diagram of Female MDR Patients Months 6-24  
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3.3 Male PanS 
Within the first 6 months, the largest proportion of patients within this time period were diagnosed as having no 
evidence of the TB bacteria, implying that these patients were simply waiting in order to be officially 
designated as “Cured,” and in fact these patients were usually the only ones designated into the “Cured” status. 
However, in younger ages, there were other patients from different test categories (Figure 7a and 7b). It should 
also be noted that the first two age groups are the only ones suffering from patients dying during the course of 
treatment, and the third age group had no deaths, but also very little “Cured” patients. 
From months 6-24, there were very few patients with positive readings for the TB infection, and many 
of these patients were eventually classified as “cured.” Month 9 contained the largest proportion of patients 
becoming cured, but that was also the month with the highest records of patients dying, though it was much 
smaller than the amount cured (Figure 8). Patients in the second age group tended to leave the system faster 
than the other age groups, with the oldest patients remaining in the treatment system longer (Figure 8b). 
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3.3.1. Month 0-6 
 
 
Figure 7: Sankey Diagram of Male PanS Patients Months 0-6 
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3.3.2. Month 6-24 
 
Figure 8: Sankey Diagram of Male PanS Patients Months 6-24 
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3.4 Female PanS 
Within the first six months, the second age group recorded the highest rates of cured patients and there were 
only occurrences of death at month 5, but there was a more even spread of different test results, especially 
compared to age groups 1 and 3, which have the majority of patients testing of negative smear and culture 
results (Figure 9a and 9c). Age group 3 also only had death at month 5, but there were sparse instances of 
patients becoming classified as cured (Figure 9c). 
During the remaining months in the treatment process, very few patients remained in the treatment 
process until month 24. Most patients were cured at month 9, and patients who died were evenly spread 
between months 9 and 12, with some occurring at month 18 (Figure 10). It should be noted that most deaths 
were patients who had not previously shown signs of the TB infection. Again, the majority of the patients 
within this demographic were showing no signs of infection, with very few having a positive smear reading. 
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3.4.1. Month 0-6 
 
Figure 9: Sankey Diagram of Female PanS Patients Months 0-6 
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3.4.2. Month 6-24 
 
Figure 10: Sankey Diagram of Female PanS Patients Months 6-24  
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3.5 Male Neither 
From the start of the time study to month 6, the highest rates of patients becoming classified as “Cured” or 
“Death” occurred up to month 3. After month 3, there were much less significant instances of patients ether 
dying or being cured, instead staying stagnant in the current test readings (Figure 11). This is better than the 
patients’ health readings declining, but there is concern that many patients aren’t improving despite treatment. 
 For the remainder of the time study, there were large portions of patients being cured at months 9 and 
18, but the highest records of death were also at month 9. No patients died at month 24, and in fact a relatively 
small amount needed to continue treatment. The youngest age group experienced the highest rates of death, with 
patients dying at months 9, 12, and 18 (Figure 12a). All age groups showed not much test reading variety, 
instead keeping consistent test readings for each time period (Figure 12). 
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3.5.1. Month 0-6 
 
Figure 11: Sankey Diagram of Male Neither Patients Months 0-6 
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3.5.2. Month 6-24 
 
Figure 12: Sankey Diagram of Male Neither Patients Months 6-24 
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3.6 Female Neither 
For the first six months, the majority of patients within this demographic have tested negative for traces of 
smear, and those who show positive signs either quickly exit the process or improve readings by testing 
negative for smear. Age group 1 is the only group with a maintained different test type for all six months 
(Figure 13a). 
During the remaining 18 months, the only age group with a test reading other than negative smear is the 
first age group (Figure 14a). Death only occurred at months 9 and 12, but the majority of the patients within 
this demographic were ultimately cured, with a smaller portion continuing treatment. Since most patients had a 
negative smear reading, most were waiting for the “Cured” status to become official, they didn’t degrade in test 
readings.  
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3.6.1. Month 0-6 
 
 
Figure 13: Sankey Diagram of Female Neither Patients Months 0-6 
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3.6.2. Month 6-24 
 
 
Figure 14: Sankey Diagram of Female Neither Patients Months 6-24 
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4. Discussion and Analysis 
In this section, the trends and comparisons between different demographics were completed. Within all six 
demographics, there were instances of patients testing positive for smear and/or culture, but then being 
considered cured in the next time period. Since it was required that patients test negative for smear/culture for at 
least two consecutive time periods in order to be considered “Cured,” this could be the result of a recording 
error or patients being clear for 2 months before the final month.  
4.1 Gender (Male vs. Female) 
When comparing the males and females in this study, it should be noted that there were many more male 
patients than female, so the male patients may offer a more complex and detailed picture than the female 
demographic. The male population experiences higher levels of death and cured patients, but since the male 
population is larger than the female, this outcome is understandable. Overall, there didn’t appear to be a 
significant difference between the gender demographics within this study.  
4.2 Month Range (0-6 Months vs. 6-24 Months) 
Since patient readings are described every month for the first six months, there is more variety in test results 
than in the months following, where the patient is only tested every 3-6 months. Since the first few months of 
treatment are the most crucial, the variety in most test results is understandable, as different treatments are 
tested in order to determine if they are effective.  
In the later months, month 9 has shown to be a major month, with many records of patients becoming 
cured or dying. After month 9, most test readings remain stagnant, with some proportions leaving the system. 
4.3 Drug Resistance Type (MDR vs. PanS vs. Neither) 
The MDR patients experienced the highest proportions of death rates among the three different drug resistant 
levels. These patients also experienced the most complexity in changing test grades. There were much more 
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variation in the amount of routes different patient test readings would take, making trend identification more 
difficult.  
The patients diagnosed with PanS resistance status tended to have much lower rates of positive smear 
and culture readings. That is, the majority of patients would test with no readings for the TB bacteria. This is 
odd, however, because there are very few reports of cured patients in the first six months, even though the 
patients tended to stay consistent in testing negative. Once the time study reached month 9, however, there were 
much greater proportions of patients becoming designated as “Cured.” This aligns with the WHO’s 
consideration that PanS patients should be cured by month 9, however, there was a decent number still within 
the treatment process. There were also few reports of patients dying, so it is unclear why it took so long for 
patients to be designated “Cured.” 
The patients neither MDR nor PanS experienced the highest rates of deaths and cured patients during the 
first 3 months of treatment, but then most patients remained stationary in status readings. There weren’t any 
particularly large ratings of cured patients until month 9, coinciding with the WHO’s predications of being 
cured within 9 months. 
4.4 Age (1 vs. 2 vs. 3) 
The youngest age group (1) was the most responsive over the course of this study. That is, younger patients 
tended “exit the system” faster (i.e. were cured or died), and over the course of time, these patients had more 
various test readings before eventually exiting the system. Older patients (age group 3) tended to stay within the 
system longer with the same test results. Age group 2 results was much more dependent on drug resistant status. 
For instance, MDR patients had much more variety in test results than PanS patients, who in turn had more 
variety than patients without a drug resistance. 
35 
 
 
 
4.5 Overall Analysis 
One of the main takeaways concerns the rate at which the patient reports back for a check-up. The standard is 2 
months, but after observing the importance of the first six months, as well as how important Month 9 is, it could 
be beneficial to schedule monthly appointments for the first 9 months of treatment instead of the first 6. This 
could allow further insight into when the patients stop drastically exiting the system and settle into a stagnant 
test result for an unexpected duration of time. However, a great emphasis should be placed on the time period 
containing the first two months, since these months contained the most variability. 
In addition to possible revision to the standard checkup rate, age should also be investigated. Since the 
younger patients are much more reactive during treatment, these patients should be more closely monitored in 
the future. 
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6. Conclusion and Future Works  
Tuberculosis is a disease that affects different portions of the world, be it active or latent. In order to better 
understand the trends of patient treatment progress, diagrams were created to display the quantities of patients 
over time according to test results. Using these diagrams, trends were identified overall and according to 
different demographics. 
The main shortcoming of this research is that only quantities of patients were tracked throughout the 
treatment process. Although this allowed general trends to be identified from the different diagrams, this did not 
track individual patient progression.  
In future studies, it would be beneficial to design a new visualization diagraming program in order to 
track typical patient progression over time according to each demographic whilst including the variation along 
the path. The inclusion of history along the entire treatment path can allow for future patients to compare his or 
her own progression path to a standard for treatment.   
  
37 
 
 
 
Bibliography 
Abdelbary, B.E., et al. Predicting treatment failure, death and drug resistance using a computed risk score 
among newly diagnosed TB patients in Tamaulipas, Mexico. Epidemiol. Infect. (2017), 145, 3020–3034. 
Cambridge University Press 2017. Retrieved 08/28/2018 doi:10.1017/S0950268817001911 
Ahuja, Shama D.et. al. Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient 
Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients. PLoS Med Vol. 9, Issue 8, 
2011. doi:10.1371/journal.pmed.1001300 
Alemasoom, Haleh et. al. Interactive Visualization of Energy Systems. The Visual Computer, 2014. DOI 
10.1109/CW.2014.39 
Chakravorty, Soumitesh et. al. Utility of Universal Sample Processing Methodology, Combining Smear 
Microscopy, Culture, and PCR, for Diagnosis of Pulmonary Tuberculosis. Journal of Clinical 
Microbiology, June 2005, pp. 2703-2708. doi:10.1128/JCM.43.6.2703–2708.2004 
Chan, Edward D. et. al. Treatment and Outcome Analysis of 205 Patients with Multidrug-resistant 
Tuberculosis. American Journal of Respiratory and Critical Care Medicine. May 2004, Vol. 169, Issue 
10, p. 1103. DOI: 10.1164/rccm.200308-1159OC 
Khan, Azam et. al. Benefits of visualization in the Mammography Problem. International Journal of Human-
Computer Studies, Vol. 83, Nov. 2015, pp. 94-113. https://doi.org/10.1016/j.ijhcs.2015.07.001 
Lab Tests Online. “Acid-Fast Bacillus (AFB) Testing.” Available at https://labtestsonline.org/tests/acid-fast-
bacillus-afb-testing. Retrieved 10/04/2018. 
Laptev, V.V., Orlov, P.A., and Dragunova, O.V. Visualization of Dynamic Data Structures with Flow Charts in 
Web Analytics. St. Petersburg State Polytechnical University Journal. Computer Science. 
Telecommunications and Control Systems, 2017, Vol. 10, No. 4, Pp. 7–16. DOI: 
10.18721/JCSTCS.10401 
38 
 
 
 
Lerner, Seth E. Analysis of Risk Factors for Progression in Patients with Pathologically Confined Prostate 
Cancers after Radical Retropubic Prostatectomy. The Journal of Urology, Vol. 156, pp. 137-143, 1996. 
https://www.ncbi.nlm.nih.gov/pubmed/8648775 
Loorak, Mona Hosseinkhani et. al. TimeSpan: Using Visualization to Explore Temporal Multi-dimensional 
Data of Stroke Patients. IEEE Transactions on Visualization and Computer Graphics, Vol. 22, No. 1, 
Jan. 2016. Digital Object Identifier no. 10.1109/TVCG.2015.2467325 
Mollel, Edson W. and Chilongola, Jaffu O. Predictors for Mortality among Multidrug-Resistant Tuberculosis 
Patients in Tanzania. (2017) Volume 2017, Article ID 9241238, 6 pages 
https://doi.org/10.1155/2017/9241238 
Philips, Lauren et. al. The association between tuberculosis and the development of insulin resistance in adults 
with pulmonary tuberculosis in the Western sub-district of the Cape Metropole region, South Africa: a 
combined cross-sectional, cohort study. BMC Infectious Diseases, Vol. 17, Issue 570, 2017. DOI 
10.1186/s12879-017-2657-5  
Raznatovska, O.M. and Khudiakov, G.V. Factors of chemoresistant pulmonary tuberculosis progression in 
patients receiving palliative treatment. Zaporozhye medical journal 2018; Vol. 20, issue 3, pp. 388-391. 
DOI: 10.14739/2310-1210. 2018.3.130829 
Senkoro, Mbazi, et. al. Smear microscopy and culture conversion rates among smear positive pulmonary 
tuberculosis patients by HIV status in Dar es Salaam, Tanzania. BMC Infectious Diseases, Vol. 10, 
Issue 210, 2010. http://www.biomedcentral.com/1471-2334/10/210 
Tiemersma EW, van der Werf MJ, Borgdorff MW, Williams BG, Nagelkerke NJD (2011) Natural History of 
Tuberculosis: Duration and Fatality of Untreated Pulmonary Tuberculosis in HIV Negative Patients A 
Systematic Review. PLoS ONE 6(4): e17601. doi:10.1371/journal.pone.0017601 
Unknown. “OBITUARY: Captain Matthew Henry Phineas Riall Sankey 1853-1925”. Minutes of the 
Proceedings, Vol. 221, Issue 1, Jan. 1926, pp. 271-271. E-ISSN 1753-7843 
39 
 
 
 
 
Vite, Aleidy Marlene Silva. (2014) Feedback System Control: optimizing drug combinations for tuberculosis 
treatment. (Doctoral Dissertation). Retrieved from ProQuest. UMI Number: 3640128 
Wallis, Robert S. et. al. Tuberculosis-advances in development of new drugs, treatment regimens, host-directed 
therapies, and biomarkers. Lancet Infect Dis Vol 16 April 2016, https://doi.org/10.1016/S1473-
3099(16)00070-0 
Wallis, Robert S. et. al. Tuberculosis biomarkers discovery: developments, needs, and challenges. Lancet Infect 
Dis, Vol. 13, pp. 362-72, 2013. http://dx.doi.org/10.1016/ 
S1473-3099(13)70034-3 
World Health Organization (WHO). Global Tuberculosis Report 2017. Geneva, Switzerland: World Health 
Organization (WHO); 2017. Retrieved 10/09/2018 
World Health Organization & Stop TB Initiative (World Health Organization). Treatment of tuberculosis: 
guidelines. World Health Organization (2010). 
Zhang, Liqun et. al. Risk Factors for Pulmonary Cavitation in Tuberculosis Patients from China. Emerging 
Microbes & Infections (2016) 5, e110; doi:10.1038/emi.2016.111 
